Pyng Medical Corp.
TSX VENTURE : PYT

Pyng Medical Corp.

September 14, 2010 17:17 ET

Pyng Medical Corp.: Simpler and Faster IO Hits the USA With the FASTx™ Sternal Intraosseous Device

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 14, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) - Gaining vascular access just got faster and simpler with the FASTx™ Sternal Intraosseous device now available in the United States. The all-in-one FASTx™ is light, compact and requires no additional tools or pre-use incisions to provide fluids, medication, and blood quickly and easily. The built-in anatomical land marking allows placement even in challenging conditions. While automatic depth-control eliminates the guesswork around how deep to go providing for clear and confident vascular access, the new target foot, now integrated into the device, provides for stability and aids in proper alignment to deploy simply. "It's these benefits that the FASTx™ provides which allows for important new vascular access options for hospital systems, EMS services, and Federal/Military customers, at a time when IO has increasingly become the recommended standard of care, that has resulted in strong early customer preference," according to Nadine Gaston, Global Vice President of Sales and Marketing. 

Sara Clark MS, RN, CCRN-CSC, Critical Care Educator at the Denver Veterans Medical Center, is one of the first US customers to purchase the FASTx™ in the weeks since US 510(k) clearance. Ms. Clark shares, "I'm excited about bringing the new technology that FASTx™ has to offer to the Denver Veterans Medical Center, not only because it will benefit the veterans we are caring for in our facility, from World War II veterans, to veterans presenting from Iraq and Afghanistan, but also because I'll have the opportunity to reach veterans from all across the United States." After evaluating alternative technologies, the Denver VA team decided to standardize on the FASTx™. According to Ms. Clark, "thanks to FASTx™, nurses will be able to provide early treatment, prevent costly bloodstream infections related to central line insertions in sub-optimal conditions, and provide the deserving care to our veterans who sacrifice life and limb."

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. 

For more information please visit us on our website at www.pyng.com.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information